Back to search

Article

Next-Generation DNA Sequencing Identifies Mutated FANCD2 Gene as a Novel Biomarker for Monitoring Early Disease Progression and Timely Therapeutic Interventions in Advanced Phase Chronic Myeloid Leukemia Patients

2023-12-20

Abstract excerpt

Chronic Myeloid Leukemia, resulting due to chromosomal aberration t(9;22) through formation of oncogenic BCR-ABL fusion oncogene. Modern BCR-ABL inhibitors, called TKIs, have revolutionized CML treatment. CML has three stages: chronic, accelerated, and blast crisis. TKIs work well in CP-CML, where patients survive as long as the normal population, but they don't work in AP- and BC-CML. Even with advances in treatm...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c09013f0-6b3f-54e5-b181-2d639f9dcdcf
DOI
10.20944/preprints202312.1499.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Next-Generation DNA Sequencing Identifies Mutated FANCD2 Gene as a Novel Biomarker for Monitoring Early Disease Progression and Timely Therapeutic Interventions in Advanced Phase Chronic Myeloid Leukemia PatientsDOI 10.20944/preprints202312.1499.v1
Next-generation DNA sequencing identifies mutated FANCD2 Gene as a novel Biomarker for monitoring early disease progression and timely therapeutic interventions in advanced phase Chronic Myeloid Leukemia patientsSemantic proximity
Whole exome sequencing identifies a novel FANCD2 gene splice site mutation associated with disease progression in chronic myeloid leukemia: Implication in targeted therapy of advanced phase CML.Semantic proximity
A retrospective case-control study for Clinical Validation of mutated ZNF208 as a novel biomarker of fatal blast crisis in Chronic Myeloid LeukemiaSemantic proximity
Identification of Prognostic and Susceptibility Markers in Chronic Myeloid Leukemia Using Next Generation Sequencing.Semantic proximity
Discovery of somatic mutations in the progression of chronic myeloid leukemia by whole-exome sequencing.Semantic proximity
Investigations on druggable gene mutations related to AML/ALL lineage genes in Advanced Phases of CML: Implications in patient-tailored therapy of blast crisis CML in TKI eraSemantic proximity
Investigations on Clinical Validation of mutated ANKRD36 as a Novel Molecular Biomarker for Monitoring Early Progression and Timely Therapeutic Interventions in Blast Crisis CMLSemantic proximity
[Analysis of Bone Marrow and Peripheral Blood Cytological Characteristics and Prognostic Research in FLT3-ITD mutated Acute Myeloid Leukemia].Semantic proximity
[Clinical Value of Detecting ABL Kinase Domain Mutations in Patients with Chronic Myeloid Leukemia Based on High-Throughput Sequencing Technology].Semantic proximity
Clinical Validation Of ANKRD36 Mutations As A Novel Biomarker For Monitoring Early Progression and Timely Clinical Interventions In Blast Crisis CMLSemantic proximity
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in OncologySemantic proximity
Integrated Genomic Analysis Identifies ANKRD36 Gene as a Novel and Common Biomarker of Disease Progression in Chronic Myeloid LeukemiaSemantic proximity
Select a neighboring publication to make it the new centre.